ARTICLE | Company News
FDA accepts brexpiprazole NDA
September 25, 2014 2:25 AM UTC
Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) and H. Lundbeck A/S (CSE:LUN) said FDA accepted for review an NDA for brexpiprazole to treat schizophrenia and as an adjunct treatment for major depressive disorder (MDD). The PDUFA date is July 11, 2015. ...